Cagrilintide + Semaglutide Blend (5mg Total)
2.5mg + 2.5mg (5mg)
$109.00
Cagrilintide + Semaglutide Blend (5mg Total)
Dual Amylin & GLP-1 Receptor Agonist Complex | Fixed-Dose Combination
The 4Balance Codex: The Synergistic Architecture of Dual-Pathway Metabolic Control.
Product Overview
This product is a precise, fixed-dose combination co-formulation containing equal parts Cagrilintide (2.5mg) and Semaglutide (2.5mg), yielding a total vial mass of 5mg. This blend represents the forefront of metabolic research, designed to investigate the additive and synergistic effects of simultaneously targeting the incretin and amylin signaling pathways. It is the primary research tool for exploring supra-additive mechanisms in body weight regulation and glucose homeostasis that exceed the capabilities of mono-agonist therapies.
Format: Lyophilized Powder (Co-formulated) Total Mass: 5mg Composition: 2.5mg Cagrilintide / 2.5mg Semaglutide
Mechanism of Action: Convergent Neuroendocrine Signaling
The scientific rationale for this blend lies in targeting distinct, yet complementary, neuronal populations within the central nervous system to maximize satiety and metabolic efficacy.
The GLP-1 Vector (Semaglutide): An acylated human GLP-1 analogue that binds to GLP-1 receptors in the hypothalamus (arcuate nucleus) and hindbrain. Its activation stimulates glucose-dependent insulin secretion, suppresses glucagon, and promotes strong sensations of satiation (fullness).
The Amylin Vector (Cagrilintide): A long-acting, non-selective amylin/calcitonin receptor agonist. It targets specific receptors in the hindbrain (area postrema and nucleus of the solitary tract), areas less accessible to GLP-1 alone. This activation enhances satiety signals and significantly slows gastric emptying.
Synergistic Amplification: By engaging different neural circuits that converge on energy balance regulation, the combination produces a more profound and sustained reduction in food intake and body weight than either compound administered individually at the same doses. The distinct mechanisms allow for multi-modal control of appetite.
Research Applications
In the 4Balance Research Array, this blend is utilized to study advanced metabolic interventions.
Supra-Additive Weight Regulation: The primary application is investigating the "CagriSema" effect—determining the extent of weight loss synergy achievable when combining hindbrain-targeted amylin agonism with broad CNS GLP-1 agonism.
Deep Glycemic Control Models: Used to study improved HbA1c reduction and beta-cell preservation in Type 2 Diabetes models where GLP-1 monotherapy has reached a plateau.
CNS Pathway Mapping: Researchers use this combination to map distinct vs. overlapping neuronal activation patterns in the brainstem and hypothalamus during feeding behavior.
Technical Specifications
Total Vial Content: 5mg Lyophilized Peptide Complex
Component Ratio: 1:1 (by mass)
Active Ingredient 1: Cagrilintide (2.5mg) - Long-acting Amylin Analogue
Active Ingredient 2: Semaglutide (2.5mg) - Long-acting GLP-1 Receptor Agonist
Solubility: Water Soluble (Requires Bacteriostatic Water for reconstitution)
Storage: Store lyophilized at -20°C. Once reconstituted, handle with care due to the complex nature of the co-formulation.
References
Kruse, T., et al. (2021). The long-acting amylin analogue cagrilintide, developed for treatment of obesity and type 2 diabetes, results in significant weight loss and improvement in glycemic control in obese and diabetic rats. Journal of Medicinal Chemistry.
Lau, J., et al. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry.
Boyle, C. N., et al. (2018). Amylin's primary action in the brain is neuroendocrine, not anorexigenic. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology.
Frias, J. P., et al. (2023). Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) in people with type 2 diabetes: a randomised, double-blind, controlled phase 2 trial. The Lancet Diabetes & Endocrinology.
Enebo, L. B., et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide in subjects with overweight or obesity: a randomised, controlled, phase 1b trial. The Lancet.
DISCLAIMER: FOR RESEARCH USE ONLY. This product is a laboratory reagent intended strictly for in-vitro research and development. It is not for human consumption, veterinary use, or therapeutic application. Bodily introduction of any kind is strictly prohibited by law.
